AtaiBeckley Price Target Raised to $15 Amid Positive Drug Trial News
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ATAI?
Source: stocktwits
- Price Target Increase: Canaccord analyst Sumant Kulkarni raised AtaiBeckley's price target from $14 to $15 while maintaining a 'Buy' rating, indicating strong confidence in the company's future performance.
- Clinical Trial Progress: Atai is preparing for its investigational psychedelic drug BPL-003 to enter late-stage trials this quarter, which is designed for treatment-resistant depression and is expected to significantly enhance the company's market position in this sector.
- Positive Market Reaction: Following President Trump's executive order to expedite psychedelic drug research, AtaiBeckley shares surged 28% on Monday, potentially marking the best single-day gain, reflecting growing optimism in the psychedelic drug industry.
- Analyst Consensus: According to Koyfin data, all 14 analysts covering ATAI rate it 'Buy' or higher, with a 12-month average price target of $13.83, representing a potential upside of about 166% from current trading levels.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATAI
Wall Street analysts forecast ATAI stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.030
Low
10.00
Averages
13.00
High
16.00
Current: 4.030
Low
10.00
Averages
13.00
High
16.00
About ATAI
AtaiBeckley Inc is a clinical-stage biotechnology company focused on developing rapid-acting, durable and convenient mental health treatments. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AtaiBeckley Price Target Raised to $15 Amid Positive Drug Trial News
- Price Target Increase: Canaccord analyst Sumant Kulkarni raised AtaiBeckley's price target from $14 to $15 while maintaining a 'Buy' rating, indicating strong confidence in the company's future performance.
- Clinical Trial Progress: Atai is preparing for its investigational psychedelic drug BPL-003 to enter late-stage trials this quarter, which is designed for treatment-resistant depression and is expected to significantly enhance the company's market position in this sector.
- Positive Market Reaction: Following President Trump's executive order to expedite psychedelic drug research, AtaiBeckley shares surged 28% on Monday, potentially marking the best single-day gain, reflecting growing optimism in the psychedelic drug industry.
- Analyst Consensus: According to Koyfin data, all 14 analysts covering ATAI rate it 'Buy' or higher, with a 12-month average price target of $13.83, representing a potential upside of about 166% from current trading levels.
See More
Midday Market Moves: Notable Stock Fluctuations
- Stanley Black & Decker Surge: Stanley Black & Decker's stock rose over 4% after the company stated that recent changes to Section 232 tariffs would not materially impact its full-year forecast, indicating strong confidence in its financial outlook.
- Fermi Stock Plunge: Shares of energy infrastructure developer Fermi fell more than 22% following the resignation of CFO Miles Everson and the recent departure of CEO Toby Neugebauer, raising concerns about the company's leadership stability and future direction.
- Biogen's Strategic Move: Biogen's stock increased nearly 3% after agreeing to pay $850 million for exclusive rights to sell felzartamab in China, which underscores its strategic expansion in the immune-related disease treatment market.
- Fertilizer Stocks Fluctuate: Fertilizer stocks experienced volatility as CF Industries rose nearly 2% due to ongoing shipping disruptions in the Strait of Hormuz, while Dow and LyondellBasell Industries also saw gains of about 4% and 2%, respectively, reflecting market reactions to supply chain challenges.
See More
Trump's Executive Order Boosts Psychedelic Stocks Rally
- Policy Catalyst: President Trump's executive order mandates the FDA to prioritize breakthrough therapy drugs, which is expected to accelerate the regulatory approval process for psychedelics, thereby enhancing commercialization pathways and boosting investor confidence in the sector.
- Clinical Trial Support: The order specifically addresses the mental health crisis among veterans, directing the Department of Veterans Affairs to promote participation in clinical trials, which is anticipated to expand the scale of psychedelic drug trials and increase market demand.
- Market Reaction: Compass Pathways saw its stock surge over 35% on Monday, marking its best single-day performance on record, while AtaiBeckley shares climbed more than 25%, reflecting heightened market sentiment and investor confidence in psychedelics.
- Analyst Expectations: Analysts project average price targets implying upside of approximately 169% for AtaiBeckley and 134% for Compass, while Definium's target suggests a potential rise of over 59% in the next year, indicating strong bullish sentiment towards these companies.
See More
Trump Fast-Tracks Approval for Psychedelic Treatments
- Accelerated Approval Process: Trump's order directs the FDA to reduce review times for certain psychedelic drugs from 6-10 months to just 1-2 months, significantly enhancing market appeal for psychedelic therapies and facilitating easier capital acquisition for related companies.
- Market Reaction: Following the new policy announcement, stocks of three biotech firms—Compass Pathways, Atai Beckley, and Definium Therapeutics—saw substantial gains on Monday, with Compass Pathways rising approximately 39% and Atai Beckley increasing by 32%, reflecting optimistic market sentiment towards psychedelic treatment prospects.
- Research Funding Support: The new order also allocates $50 million from the Department of Health and Human Services to advance private sector research into psychedelic therapies, providing additional resources for related companies to develop new treatments.
- Historical Return and Market Opportunities: Trump's directive signifies a new era for psychedelic treatments, potentially expediting the reclassification of currently Schedule I psychedelic compounds, and companies that can bring these new therapies to market first are likely to gain a competitive edge.
See More
Trump Signs Executive Order to Accelerate Psychedelic Drug Reviews
- Market Reaction: Following President Trump's executive order, shares of psychedelic drug developers surged in premarket trading, with Atai Life Sciences up 21%, Definium Therapeutics rising 15%, and Compass Pathways climbing 26%, indicating strong market confidence in the psychedelic sector.
- Executive Order Details: The order directs the FDA to expedite reviews of psychedelic drugs, particularly ibogaine for treating PTSD, depression, and addiction, potentially reducing review times from 6-10 months to just 1-2 months, significantly enhancing the industry's outlook.
- Government Funding Support: Trump announced a $50 million allocation for federal research into ibogaine, providing crucial financial backing for the development of psychedelic drugs and further propelling industry growth.
- Regulatory Risk Mitigation: Analysts noted that the executive order represents a government endorsement of psychedelics, reducing regulatory risks and potentially facilitating legislative efforts to expand access to psychedelic therapies, reflecting bipartisan interest and support in this field.
See More
FDA Prioritizes Review of Psychedelic Treatments
- Regulatory Push for Acceleration: President Trump signed an executive order aimed at expediting the development and review of psychedelic drugs, with the FDA prioritizing treatments that have shown positive results, thereby shortening regulatory timelines and expanding research opportunities.
- COMP360 Therapy Progress: Compass Pathways' COMP360 synthetic psilocybin has demonstrated rapid relief within a day for patients in late-stage trials, with effects lasting up to six months after just one or two doses, indicating its potential in treating depression.
- Positive Market Reaction: Compass Pathways' stock gained over 2% overnight on Sunday, reflecting market support for the White House's initiative to accelerate research and approval of psychedelic treatments, with peers like Enveric Biosciences and ATAI Life Sciences also seeing increases of over 3.5% and 1.1%, respectively.
- Investor Sentiment Surge: On Stocktwits, retail sentiment for Compass Pathways remains in 'extremely bullish' territory, with message volume surging by 2,000% over the past week, indicating strong investor optimism regarding COMP360's potential FDA approval.
See More
AtaiBeckley Price Target Raised to $15 Amid Positive Drug Trial News
- Price Target Increase: Canaccord analyst Sumant Kulkarni raised AtaiBeckley's price target from $14 to $15 while maintaining a 'Buy' rating, indicating strong confidence in the company's future performance.
- Clinical Trial Progress: Atai is preparing for its investigational psychedelic drug BPL-003 to enter late-stage trials this quarter, which is designed for treatment-resistant depression and is expected to significantly enhance the company's market position in this sector.
- Positive Market Reaction: Following President Trump's executive order to expedite psychedelic drug research, AtaiBeckley shares surged 28% on Monday, potentially marking the best single-day gain, reflecting growing optimism in the psychedelic drug industry.
- Analyst Consensus: According to Koyfin data, all 14 analysts covering ATAI rate it 'Buy' or higher, with a 12-month average price target of $13.83, representing a potential upside of about 166% from current trading levels.
See More
Midday Market Moves: Notable Stock Fluctuations
- Stanley Black & Decker Surge: Stanley Black & Decker's stock rose over 4% after the company stated that recent changes to Section 232 tariffs would not materially impact its full-year forecast, indicating strong confidence in its financial outlook.
- Fermi Stock Plunge: Shares of energy infrastructure developer Fermi fell more than 22% following the resignation of CFO Miles Everson and the recent departure of CEO Toby Neugebauer, raising concerns about the company's leadership stability and future direction.
- Biogen's Strategic Move: Biogen's stock increased nearly 3% after agreeing to pay $850 million for exclusive rights to sell felzartamab in China, which underscores its strategic expansion in the immune-related disease treatment market.
- Fertilizer Stocks Fluctuate: Fertilizer stocks experienced volatility as CF Industries rose nearly 2% due to ongoing shipping disruptions in the Strait of Hormuz, while Dow and LyondellBasell Industries also saw gains of about 4% and 2%, respectively, reflecting market reactions to supply chain challenges.
See More
Trump's Executive Order Boosts Psychedelic Stocks Rally
- Policy Catalyst: President Trump's executive order mandates the FDA to prioritize breakthrough therapy drugs, which is expected to accelerate the regulatory approval process for psychedelics, thereby enhancing commercialization pathways and boosting investor confidence in the sector.
- Clinical Trial Support: The order specifically addresses the mental health crisis among veterans, directing the Department of Veterans Affairs to promote participation in clinical trials, which is anticipated to expand the scale of psychedelic drug trials and increase market demand.
- Market Reaction: Compass Pathways saw its stock surge over 35% on Monday, marking its best single-day performance on record, while AtaiBeckley shares climbed more than 25%, reflecting heightened market sentiment and investor confidence in psychedelics.
- Analyst Expectations: Analysts project average price targets implying upside of approximately 169% for AtaiBeckley and 134% for Compass, while Definium's target suggests a potential rise of over 59% in the next year, indicating strong bullish sentiment towards these companies.
See More
Trump Fast-Tracks Approval for Psychedelic Treatments
- Accelerated Approval Process: Trump's order directs the FDA to reduce review times for certain psychedelic drugs from 6-10 months to just 1-2 months, significantly enhancing market appeal for psychedelic therapies and facilitating easier capital acquisition for related companies.
- Market Reaction: Following the new policy announcement, stocks of three biotech firms—Compass Pathways, Atai Beckley, and Definium Therapeutics—saw substantial gains on Monday, with Compass Pathways rising approximately 39% and Atai Beckley increasing by 32%, reflecting optimistic market sentiment towards psychedelic treatment prospects.
- Research Funding Support: The new order also allocates $50 million from the Department of Health and Human Services to advance private sector research into psychedelic therapies, providing additional resources for related companies to develop new treatments.
- Historical Return and Market Opportunities: Trump's directive signifies a new era for psychedelic treatments, potentially expediting the reclassification of currently Schedule I psychedelic compounds, and companies that can bring these new therapies to market first are likely to gain a competitive edge.
See More
Trump Signs Executive Order to Accelerate Psychedelic Drug Reviews
- Market Reaction: Following President Trump's executive order, shares of psychedelic drug developers surged in premarket trading, with Atai Life Sciences up 21%, Definium Therapeutics rising 15%, and Compass Pathways climbing 26%, indicating strong market confidence in the psychedelic sector.
- Executive Order Details: The order directs the FDA to expedite reviews of psychedelic drugs, particularly ibogaine for treating PTSD, depression, and addiction, potentially reducing review times from 6-10 months to just 1-2 months, significantly enhancing the industry's outlook.
- Government Funding Support: Trump announced a $50 million allocation for federal research into ibogaine, providing crucial financial backing for the development of psychedelic drugs and further propelling industry growth.
- Regulatory Risk Mitigation: Analysts noted that the executive order represents a government endorsement of psychedelics, reducing regulatory risks and potentially facilitating legislative efforts to expand access to psychedelic therapies, reflecting bipartisan interest and support in this field.
See More
FDA Prioritizes Review of Psychedelic Treatments
- Regulatory Push for Acceleration: President Trump signed an executive order aimed at expediting the development and review of psychedelic drugs, with the FDA prioritizing treatments that have shown positive results, thereby shortening regulatory timelines and expanding research opportunities.
- COMP360 Therapy Progress: Compass Pathways' COMP360 synthetic psilocybin has demonstrated rapid relief within a day for patients in late-stage trials, with effects lasting up to six months after just one or two doses, indicating its potential in treating depression.
- Positive Market Reaction: Compass Pathways' stock gained over 2% overnight on Sunday, reflecting market support for the White House's initiative to accelerate research and approval of psychedelic treatments, with peers like Enveric Biosciences and ATAI Life Sciences also seeing increases of over 3.5% and 1.1%, respectively.
- Investor Sentiment Surge: On Stocktwits, retail sentiment for Compass Pathways remains in 'extremely bullish' territory, with message volume surging by 2,000% over the past week, indicating strong investor optimism regarding COMP360's potential FDA approval.
See More
